Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Dolutegravir

Client Email

Product

Dolutegravir
3-Aminobutanoic Acid
CAS 1335210-23-5
CAS 1206102-11-5
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

Contact Supplier

Axplora- The partner of choice for complex APIs.

Contact Supplier

Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

Contact Supplier

Dolutegravir

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 24 USDMF, 8 EU WC, 2 KDMF, 12 NDC API, 33 Listed Suppliers, $ API Reference Price

50 API Suppliers
24 USDMF
8 EU WC
2 KDMF
12 NDC API
33 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Imports

INTERMEDIATES

37 API Suppliers

37 API Suppliers

FINISHED DOSAGE FORMULATIONS

105 FDF Dossiers, 28 FDA Orange Book, 10 Europe, 7 Canada, 1 Australia, 57 South Africa, 2 Listed Dossiers

105 FDF Dossiers
28 FDA Orange Book
10 Europe
7 Canada
1 Australia
57 South Africa
2 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG

TABLET;ORAL - EQ 10MG BASE
TABLET;ORAL - EQ 25MG BASE
TABLET;ORAL - EQ 50MG BASE
TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Rochem International Inc, 14 SPI Pharma, 2 Seqens, 3 DKSH, 2 Jai Radhe Sales, 4 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 11 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 20 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 22 Kerry, 12 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 13 Roquette, 2 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

70 Fillers, Diluents & Binders, 33 Direct Compression, 22 Coating Systems & Additives, 20 Disintegrants & Superdisintegrants, 19 Granulation, 19 Lubricants & Glidants, 18 Thickeners and Stabilizers, 17 Co-Processed Excipients, 16 Solubilizers, 16 Controlled & Modified Release, 13 Chewable & Orodispersible Aids, 12 Parenteral, 11 Taste Masking, 10 Topical, 5 Film Formers & Plasticizers, 3 API Stability Enhancers, 3 Coloring Agents, 2 Surfactant & Foaming Agents, 2 Rheology Modifiers, 2 Emulsifying Agents

70 Fillers, Diluents & Binders
33 Direct Compression
22 Coating Systems & Additives
20 Disintegrants & Superdisintegrants
19 Granulation
19 Lubricants & Glidants
18 Thickeners and Stabilizers
17 Co-Processed Excipients
16 Solubilizers
16 Controlled & Modified Release
13 Chewable & Orodispersible Aids
12 Parenteral
11 Taste Masking
10 Topical
5 Film Formers & Plasticizers
3 API Stability Enhancers
3 Coloring Agents
2 Surfactant & Foaming Agents
2 Rheology Modifiers
2 Emulsifying Agents

DIGITAL CONTENT

6 DATA COMPILATION #PharmaFlow, 2 STOCK RECAP #PipelineProspector, 125 NEWS #PharmaBuzz

6 DATA COMPILATION #PharmaFlow
2 STOCK RECAP #PipelineProspector
125 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 12 Finished Drug Prices, 32 Annual Reports

3 US Medicaid Prescriptions
12 Finished Drug Prices
32 Annual Reports

MARKET PLACE

8 APIs, 8 FDF Dossiers

8 APIs
8 FDF Dossiers

PATENTS & EXCLUSIVITIES

36 US Patents, 5 US Exclusivities, 1 Health Canada Patents

36 US Patents
5 US Exclusivities
1 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ API Ref.Price (USD/KG) : 393 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

36 All

01 36VIIV HLTHCARE

filter Patent Number Reset all filters

36 All

01 17125879

02 88129385

03 89242986

04 110426780

05 111234985

06 112011506

07 88129385*PED

08 89242986*PED

filter API Patent Reset all filters

36 All

01 18Y

02 18Blank

filter FDF Patent Reset all filters

36 All

01 20Y

02 16Blank

filter Expiration Date Reset all filters

36 All

01 12025-04-21

02 82027-10-05

03 82028-04-05

04 82029-12-08

05 82030-06-08

06 22031-01-24

07 12038-09-05

US Patents
US Exclusivities
Health Canada Patents

Product Main Page

01

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-04-21

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

US Patent Number : 7125879

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210192

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2025-04-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-01-24

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

US Patent Number : 10426780

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210192

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2031-01-24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-01-24

DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 11234985

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 211994

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2031-01-24

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-05

DOLUTEGRAVIR SODIUM

US Patent Number : 8129385

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 204790

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-10-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-05

DOLUTEGRAVIR SODIUM

US Patent Number : 8129385

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 204790

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-10-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210192

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

DOLUTEGRAVIR SODIUM

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 204790

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-12-08

DOLUTEGRAVIR SODIUM

US Patent Number : 9242986

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 213983

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Discovery on Target

Not Confirmed

VIIV HLTHCARE

Discovery on Target

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-10-05

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

US Patent Number : 8129385

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205551

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-10-05

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?